ACOTEC SCIEN.H. DL-00001 Net Assets
ACOTEC SCIEN.H. DL-00001 net assets. Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) has net assets worth €1.48 Billion EUR (≈ $1.73 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.87 Billion ≈ $2.18 Billion USD) and total liabilities (€392.01 Million ≈ $458.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of ACOTEC SCIEN.H. DL-00001 to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.48 Billion |
| % of Total Assets | 79.02% |
| Annual Growth Rate | 5.16% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.81 |
Net Assets of ACOTEC SCIEN.H. DL-00001 (2021–2025)
Net assets of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025. This chart illustrates how ACOTEC SCIEN.H. DL-00001's net assets have evolved over time, based on quarterly financial data. See how leveraged is ACOTEC SCIEN.H. DL-00001's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for ACOTEC SCIEN.H. DL-00001 (2021–2025)
The table below shows the annual net assets of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025. For live market cap and overall valuation, see 7W3 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.48 Billion ≈ $1.73 Billion |
+9.35% |
| 2024-12-31 | €1.35 Billion ≈ $1.58 Billion |
+4.11% |
| 2023-12-31 | €1.30 Billion ≈ $1.52 Billion |
+1.60% |
| 2022-12-31 | €1.28 Billion ≈ $1.49 Billion |
+5.71% |
| 2021-12-31 | €1.21 Billion ≈ $1.41 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ACOTEC SCIEN.H. DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23380800000.0% over the analyzed period, indicating profitable operations and earnings retention.
ACOTEC SCIEN.H. DL-00001 Net Assets Breakdown (December 2025)
ACOTEC SCIEN.H. DL-00001 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.51 Billion | 102.37% |
| Total Equity | €1.48 Billion | 100.00% |
ACOTEC SCIEN.H. DL-00001 Competitors by Market Cap
The table below lists competitors of ACOTEC SCIEN.H. DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pizza Pizza Royalty Corp.
TO:PZA
|
$197.85 Million |
|
Henan BCCY Environmental Energy Co. Ltd
SHE:300614
|
$197.92 Million |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
$197.95 Million |
|
GNCO Co. Ltd
KQ:065060
|
$197.96 Million |
|
Maxim Power Corp.
TO:MXG
|
$197.73 Million |
|
Z Squared Inc.
NASDAQ:ZSQR
|
$197.69 Million |
|
Thien Long Group Corp
VN:TLG
|
$197.68 Million |
|
LF Capital Acquisition Corp. II Units
NASDAQ:LFACU
|
$197.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACOTEC SCIEN.H. DL-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,349,816,000 to 1,476,085,000, a change of 126,269,000 (9.4%).
- Net income of 119,184,000 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €119.18 Million | +8.07% |
| Other Changes | €7.08 Million | +0.48% |
| Total Change | €- | 9.35% |
Book Value vs Market Value Analysis
This analysis compares ACOTEC SCIEN.H. DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.85 | €0.54 | x |
| 2022-12-31 | €4.07 | €0.54 | x |
| 2023-12-31 | €4.14 | €0.54 | x |
| 2024-12-31 | €4.31 | €0.54 | x |
| 2025-12-31 | €4.71 | €0.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACOTEC SCIEN.H. DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.49%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.27x
- Recent ROE (8.07%) is above the historical average (2.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -6.55% | -26.03% | 0.23x | 1.08x | €-199.80 Million |
| 2022 | 5.50% | 17.73% | 0.28x | 1.11x | €-57.47 Million |
| 2023 | 1.12% | 3.06% | 0.29x | 1.24x | €-115.17 Million |
| 2024 | 3.87% | 9.79% | 0.32x | 1.23x | €-82.70 Million |
| 2025 | 8.07% | 18.49% | 0.35x | 1.27x | €-28.42 Million |
Industry Comparison
This section compares ACOTEC SCIEN.H. DL-00001's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $50,533,572,702
- Average return on equity (ROE) among peers: -868.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACOTEC SCIEN.H. DL-00001 (7W3) | €1.48 Billion | -6.55% | 0.27x | $197.85 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $161.36K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $432.90 Billion | 11.47% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $787.37 Million | 25.14% | 0.10x | $711.77 Million |
| HeraMED Limited (1I4) | $76.93K | -8590.94% | 35.29x | $27.68 Million |
| Medtronic PLC (2M6) | $51.83 Billion | 6.83% | 0.92x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $-94.34 Million | 0.00% | 0.00x | $299.00 Million |
| AVITA Medical Inc (51KB) | $72.40 Million | -58.05% | 0.14x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more